Africa Pharmaceutical Industry: Market Size, Trends & Data

Africa’s pharmaceutical industry is one of the fastest-growing and most import-dependent healthcare markets in the world at the same time — and understanding why both things are true is the key to spotting where the real opportunity sits.

Quick Answer

Africa’s pharmaceutical market is valued at roughly $27–29 billion, with most forecasts projecting steady growth through the early 2030s. Yet the continent still imports an estimated 60–70% of the medicines it consumes, because local manufacturing is concentrated in just a handful of countries: eight nations — half of them in North Africa — account for 85% of Africa’s 690 pharmaceutical production facilities, and even those facilities typically run at only 30–60% of capacity. That gap between demand and local supply is why international manufacturers, API suppliers, and equipment providers continue to treat Africa — and West Africa in particular — as a priority growth market.

Here Is the Bottom Line

Africa’s pharmaceutical market sits around $27–29 billion today, with most analysts projecting it to grow through 2030–2035, though estimates vary widely depending on whether Middle East markets are included.
60–70% of medicines consumed in Africa are imported, primarily from India and China, due to limited domestic manufacturing capacity and high local production costs.
Local manufacturers exist in fewer than half of Africa’s 54 countries, and production is concentrated: just eight countries hold 85% of the continent’s ~690 pharmaceutical facilities.
Egypt leads the market with roughly 38% share, South Africa has the most advanced regulatory infrastructure, and Nigeria is projected to be the highest-growth market through 2032.
New regulatory harmonization — through the African Medicines Agency (AMA) and the African Medicines Regulatory Harmonisation (AMRH) programme — is starting to streamline approvals across borders, making regional manufacturing and distribution more viable.
For manufacturers and suppliers, the practical opportunity is regional: events connecting African buyers, distributors, and manufacturers directly — like Pharma West Africa — are becoming the fastest route into this fragmented but fast-growing market.

How Big Is Africa’s Pharmaceutical Industry?

Market size estimates for Africa’s pharmaceutical industry vary significantly depending on methodology and geographic scope, which is worth understanding before quoting any single figure.

Source Estimate	Market Size	Forecast	CAGR
Africa-only estimate (Grand View Research)	$27.65B (2024)	$36.96B by 2033	3.3%
Africa-only estimate (Persistence Market Research)	$29.3B (2025)	$44.1B by 2032	6.1%
Middle East & Africa combined	$85.27B (2026)	$150.55B by 2035	6.52%
Sub-Saharan Africa only	$8B (2025)	$13B by 2030	10.2%

The wide spread reflects a genuinely fragmented market — some reports fold in the Middle East, others isolate Sub-Saharan Africa, and definitions of “pharmaceutical market” (retail sales vs. total spend, including or excluding diagnostics) differ between research firms. The consistent theme across nearly every estimate, though, is that Sub-Saharan Africa is the fastest-growing sub-region, and generics remain the dominant product category, capturing close to half of total market share.

Why Africa Still Imports Most of Its Medicines

Africa’s manufacturing capacity simply hasn’t kept pace with its population growth and disease burden. A few structural reasons explain the gap:

Manufacturing is geographically concentrated. Of the continent’s roughly 690 pharmaceutical production facilities, 85% sit in just eight countries — half of them in North Africa (Egypt, Morocco, Tunisia, and Algeria among the leaders).
Existing facilities run under capacity. Most African pharmaceutical plants operate at only 30–60% of capacity, well below the 70%+ utilization typical of more mature manufacturing economies.
Production costs remain structurally higher. According to UNIDO, African pharmaceutical producers face production costs averaging 30–50% higher than their Asian counterparts, driven by inefficient supply chains, outdated equipment, and unreliable energy supply.
Active pharmaceutical ingredients (APIs) are almost entirely imported, mainly from India and China, leaving local manufacturers exposed to currency and shipping volatility even when they do produce finished products locally.
Regulatory fragmentation across 54 countries has historically discouraged cross-border investment, though this is actively changing (see below).

The upside: despite higher average costs, finished-product manufacturing in countries like Ethiopia and Nigeria can actually be around 15% cheaper than importing from India for certain product categories — a cost advantage that’s driving renewed interest in localized production, particularly for high-volume generics.

Regulatory Harmonization Is Changing the Landscape

For decades, one of the biggest barriers to pharmaceutical trade and manufacturing investment in Africa was regulatory fragmentation — a product approved in one country often had to go through a near-identical process to be approved in the next. Two initiatives are changing that:

The African Medicines Agency (AMA) — a newly established continental body designed to streamline and harmonize drug approvals across member states, reducing duplication and speeding up market access.
The African Continental Free Trade Area (AfCFTA), alongside the existing African Medicines Regulatory Harmonisation (AMRH) programme, which is gradually aligning registration standards and easing cross-border pharmaceutical trade.

For manufacturers and suppliers, this matters directly: harmonized approvals mean a product registered in one hub market can move toward faster approval elsewhere on the continent, lowering the cost of regional expansion — including into West Africa’s largest market, Nigeria.

Country Snapshot: Who Leads Africa’s Pharmaceutical Market

Country	Position	Key Characteristic
Egypt	Market share leader (~38%)	Strong regional export capabilities and government procurement concentration
South Africa	Most advanced regulatory infrastructure	Sophisticated distribution and manufacturing base
Nigeria	Highest-growth market through 2032	Rapid urbanization, middle-class expansion, largest population base in West Africa
Ethiopia	Emerging low-cost manufacturing hub	Competitive local production costs relative to imports
Morocco / Tunisia / Algeria	North African manufacturing concentration	Part of the eight countries holding 85% of continental production capacity

Nigeria’s position is particularly notable for suppliers focused on West Africa: it combines the region’s largest population, the fastest projected growth rate through 2032, and a manufacturing base still heavily reliant on imported raw materials, machinery, and finished products — a combination that keeps demand high on both the manufacturing and distribution sides.

Key Growth Drivers Across the Continent

Rapid urbanization, which is accelerating the shift toward non-communicable diseases (NCDs) like diabetes, hypertension, and cardiovascular conditions — all requiring long-term medication use.
Rising middle-class purchasing power, expanding the addressable market for both generics and, increasingly, specialty products.
Generics dominance, with generic drugs capturing close to half of total market share as patents on branded drugs expire and local manufacturers step in.
Growing interest in biologics and biosimilars, including localized manufacturing of GLP-1 agonists — a segment expected to be among the fastest-growing through 2032.
International licensing partnerships, such as Eli Lilly’s 2024 agreement licensing production of its rheumatoid arthritis drug to Egypt’s Eva Pharma, with plans to supply 49 African countries — a model likely to be replicated as regulatory harmonization matures.

Africa vs. Asia: The Manufacturing Cost Comparison

Factor	Africa	Asia (India/China benchmark)
Average production cost	30–50% higher (UNIDO)	Baseline / lowest-cost benchmark
Facility capacity utilization	30–60%	70%+ typical
API self-sufficiency	Low — imports dominate	High — major global API exporter
Cost advantage in select markets	~15% cheaper in Ethiopia/Nigeria for some finished products	N/A
Regulatory landscape	Fragmenting → harmonizing (AMA, AMRH, AfCFTA)	Long-established national frameworks

This is the paradox international suppliers need to understand: Africa is more expensive to manufacture in on average, but select markets — Nigeria and Ethiopia among them — are already demonstrating that localized, well-invested production can beat import costs on specific product lines. That’s the gap driving current investment interest.

Frequently Asked Questions

How big is the pharmaceutical market in Africa?
Estimates range from roughly $27 billion to $29 billion for Africa alone (excluding the Middle East), with most forecasts projecting growth to somewhere between $37 billion and $44 billion by the early 2030s, depending on the research methodology used.

What percentage of medicines in Africa are imported?
An estimated 60–70% of medicines consumed across Africa are imported, primarily from India and China, due to limited domestic manufacturing capacity in most countries.

Which African country has the largest pharmaceutical market?
Egypt currently leads with an estimated 38% market share, supported by strong regional export capabilities. South Africa has the most sophisticated regulatory and manufacturing infrastructure, while Nigeria is projected to be the fastest-growing market through 2032.

Why is pharmaceutical manufacturing so concentrated in a few African countries?
Roughly 85% of the continent’s approximately 690 pharmaceutical production facilities are located in just eight countries, largely due to more developed infrastructure, more established regulatory systems, and greater access to financing in those markets.

Is it cheaper to manufacture medicines in Africa than to import them?
It depends on the country and product. On average, African production costs run 30–50% higher than in Asia. However, for certain finished products, manufacturing in Ethiopia or Nigeria can be around 15% cheaper than importing from India — making localized production increasingly attractive for high-volume generics.

What is the African Medicines Agency (AMA)?
The AMA is a newly established continental regulatory body designed to harmonize and streamline drug approval processes across African Union member states, reducing duplication and accelerating market access for manufacturers.

How can international manufacturers and suppliers enter the African pharmaceutical market?
Given the market’s regulatory fragmentation and reliance on local distribution networks, direct engagement — through regional distributors, licensing partnerships, or trade exhibitions with hosted buyer programmes — remains the most effective entry route, particularly in high-growth hub markets like Nigeria.

The Bottom Line

Africa’s pharmaceutical industry is growing steadily, but it remains structurally import-dependent: manufacturing capacity is concentrated in a handful of countries, existing facilities run well under capacity, and production costs remain higher than in Asia on average. At the same time, regulatory harmonization through the AMA and AfCFTA, plus a genuine cost advantage in specific hub markets like Nigeria and Ethiopia, are starting to shift the balance toward localized production. For manufacturers and suppliers, West Africa — anchored by Nigeria’s position as the region’s fastest-growing market — remains one of the most direct paths into this opportunity.

Book a stand or register to visit at Pharma West Africa 2027 to meet the manufacturers, distributors, and regulators shaping this market in person.

Sources

Grand View Research — Africa Pharmaceutical Market Size | Industry Report, 2033
Persistence Market Research — Africa Pharmaceuticals Market Forecast, 2025–2032
Towards Healthcare — Middle East and Africa Pharmaceutical Market Sizing
MarketDataForecast — Africa Pharmaceutical Market Size & Share, 2033 (citing African Union and UNIDO data)
Medi-Tech Insights — Sub-Saharan Africa (SSA) Pharmaceuticals Market Size & Forecast
Pharma West Africa — Market Overview

Market size figures vary meaningfully between research providers due to differing scope and methodology. Figures here are presented as ranges for that reason and should be reconfirmed against the original report before use in formal reporting or investor materials.

Article Tags: